Rhythm Pharmaceuticals (RYTM) Cash from Operations (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Cash from Operations data on file, last reported at 44185000.0 in Q1 2026.

• Cash from Operations for Q1 2026 came in at 44185000.0, down 9.5% year-over-year; the trailing twelve-month figure through Mar 2026 was 119509000.0 (down 5.31% YoY), and the FY2025 annual result was 115675000.0, down 1.58% from the prior year.
• Cash from Operations declined to 44185000.0 in Q1 2026 per RYTM's latest filing, from 25389000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 18845000.0 in Q4 2024 and troughed at 53632000.0 in Q1 2022.
• A 5-year average of 34313176.47 and a median of 34000000.0 in 2022 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations tumbled 59.95% in 2022, then surged 37.75% in 2023.
• A 5-year view of Cash from Operations shows it stood at 34000000.0 in 2022, then gained by 13.58% to 29383000.0 in 2023, then surged by 35.86% to 18845000.0 in 2024, then tumbled by 34.73% to 25389000.0 in 2025, then sank by 74.03% to 44185000.0 in 2026.
• Business Quant data shows RYTM's Cash from Operations at 44185000.0 in Q1 2026, 25389000.0 in Q4 2025, and 26622000.0 in Q3 2025.